Advertisement
Mayo Clinic Proceedings Home
MCP Digital Health Home

Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic

      Abstract

      Objectives

      To determine the indications for prediagnostic testing, subsequent diagnoses found, and follow-up practices in patients who were incidentally diagnosed with monoclonal gammopathy of undetermined significance (MGUS).

      Patients and Methods

      From our prospective MGUS database, we identified 329 patients residing in southeastern Minnesota who were diagnosed from January 1, 2011, through December 31, 2014, and followed up at Mayo Clinic.

      Results

      Most test orders came from nonhematologists (n=310, 94.2%). The top 5 indications were neuropathy (n=65, 19.8%), renal disease (n=45, 13.7%), anemia (n=42, 12.8%), bone disorder or connective tissue pain (n=42, 12.8%), and cutaneous disease (n=19, 5.8%). Hypercalcemia was an infrequent indication (n=9, 2.7%). The final diagnosis for all neuropathy evaluations was sensory/motor neuropathy—not otherwise specified, with 18.7% having IgM MGUS. Chronic kidney disease—not otherwise specified, iron deficiency, and osteoporosis/osteopenia were the most common subsequent diagnoses for test indications of renal disease, anemia, and bone disorder or connective tissue pain, respectively. Most patients (n=213, 64.7%) had 1 or more follow-up visit during the study period. A minority were followed by hematologists (43.5%, n=143). Patients with low-risk MGUS comprised 45.0% (n=148) of the cohort. Male patients and younger patients were more likely to be followed up than their counterparts (P<.01). About one-third (n=27, 32.1%) of patients 80 years or older (n=84) continued to have regular follow-up visits. Hematologists were more likely to follow patients with MGUS more closely than nonhematologists (P<.001). However, the intensity of follow-up was not based on MGUS risk.

      Conclusion

      Monoclonal protein testing is commonly performed for signs and symptoms not typically associated with lymphoplasmacytic malignancies. There is a significant variation in MGUS follow-up between hematologists and nonhematologists (P<.001) that is not based on risk factors or clinical practice guidelines.

      Abbreviations and Acronyms:

      CRAB (hypercalcemia, renal insufficiency, anemia, and bone pain/lesions), FLC (free light chain), LPM (lymphoplasmacytic malignancy), MGUS (monoclonal gammopathy of undetermined significance), NOS (not otherwise specified), QOL (quality of life), SPEP (serum protein electrophoresis)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kyle R.A.
        • Therneau T.M.
        • Rajkumar S.V.
        • et al.
        Prevalence of monoclonal gammopathy of undetermined significance.
        N Engl J Med. 2006; 354: 1362-1369
        • Landgren O.
        • Graubard B.
        • Kumar S.
        • et al.
        Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.
        Blood Cancer J. 2017; 7: e618
        • Fermand J.P.
        • Bridoux F.
        • Dispenzieri A.
        • et al.
        Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.
        Blood. 2018; 132: 1478-1485
        • Go R.S.
        • Swanson K.M.
        • Sangaralingham L.R.
        • Habermann E.B.
        • Shah N.D.
        Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care.
        Leukemia. 2016; 30: 1443-1446
        • Therneau T.M.
        • Kyle R.A.
        • Melton III, L.J.
        • et al.
        Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.
        Mayo Clin Proc. 2012; 87: 1071-1079
        • Go R.S.
        • Rajkumar S.V.
        How I manage monoclonal gammopathy of undetermined significance.
        Blood. 2018; 131: 163-173
        • Liberati A.
        An unfinished trip through uncertainties.
        BMJ. 2004; 328: 531
        • Cole C.E.
        • Ballandby R.
        • Schroeder J.E.
        • et al.
        Assessment of psychological distress in patients suffering from hematological disorders [abstract].
        Blood. 2007; 110: 636
        • Hildebrandt M.A.T.
        • Callender R.A.
        • Belachew A.A.
        • et al.
        Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies [abstract].
        J Clin Oncol. 2018; 36: 8049
        • Maatouk I.
        • He S.
        • Hummel M.
        • et al.
        Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma.
        Blood Cancer J. 2019; 9: 9
        • Kyle R.A.
        • Therneau T.M.
        • Rajkumar S.V.
        • et al.
        A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
        N Engl J Med. 2002; 346: 564-569
        • Turesson I.
        • Kovalchik S.A.
        • Pfeiffer R.M.
        • et al.
        Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.
        Blood. 2014; 123: 338-345
        • Bird J.
        • Behrens J.
        • Westin J.
        • et al.
        • Haemato-oncology Task Force of the British Committee for Standards in Haematology
        • UK Myeloma Forum and Nordic Myeloma Study Group
        UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
        Br J Haematol. 2009; 147: 22-42
        • Kyle R.A.
        • Durie B.G.
        • Rajkumar S.V.
        • et al.
        • International Myeloma Working Group
        Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
        Leukemia. 2010; 24: 1121-1127
        • Berenson J.R.
        • Anderson K.C.
        • Audell R.A.
        • et al.
        Monoclonal gammopathy of undetermined significance: a consensus statement.
        Br J Haematol. 2010; 150: 28-38
        • Go R.S.
        • Heien H.C.
        • Sangaralingham L.R.
        • Habermann E.B.
        • Shah N.D.
        Monoclonal gammopathy of undetermined significance: follow-up patterns in the United States and concordance with clinical practice guidelines.
        Mayo Clin Proc Innov Qual Outcomes. 2017; 1: 161-169
        • van de Donk N.W.
        • Palumbo A.
        • Johnsen H.E.
        • et al.
        • European Myeloma Network
        The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
        Haematologica. 2014; 99: 984-996
        • Rajkumar S.V.
        • Kyle R.A.
        • Therneau T.M.
        • et al.
        Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
        Blood. 2005; 106: 812-817
        • Kelly Jr., J.J.
        • Kyle R.A.
        • O’Brien P.C.
        • Dyck P.J.
        Prevalence of monoclonal protein in peripheral neuropathy.
        Neurology. 1981; 31: 1480-1483
        • Chaudhry H.M.
        • Mauermann M.L.
        • Rajkumar S.V.
        Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management.
        Mayo Clin Proc. 2017; 92: 838-850
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Ravindran A.
        • Gonsalves W.I.
        • Hashmi S.K.
        • et al.
        Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely?.
        Leuk Lymphoma. 2017; 58: 251-252
      1. Kaiser Family Foundation state health facts. The Henry J. Kaiser Family Foundation website.
        https://www.kff.org
        Date accessed: February 17, 2019
        • García-Sanz R.
        • Montoto S.
        • Torrequebrada A.
        • et al.
        • Spanish Group for the Study of Waldenström Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematological Malignancies)
        Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
        Br J Haematol. 2001; 115: 575-582
        • Kyle R.A.
        • Gertz M.A.
        Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
        Semin Hematol. 1995; 32: 45-59
        • Kyle R.A.
        • Gertz M.A.
        • Witzig T.E.
        • et al.
        Review of 1027 patients with newly diagnosed multiple myeloma.
        Mayo Clin Proc. 2003; 78: 21-33
        • Doyle L.M.
        • Gundrum J.D.
        • Farnen J.P.
        • Wright L.J.
        • Kranig R.H.I.T.
        • Go R.S.
        Determining why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients with monoclonal gammopathy of undetermined significance (MGUS) [abstract].
        Blood. 2009; 114: 4883
      2. Cancer stat facts: myeloma. National Cancer Institute: Surveillance, Epidemiology, and End Results Program website.
        • Leung N.
        • Bridoux F.
        • Batuman V.
        • et al.
        The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group [published correction appears in Nat Rev Nephrol. 2019;15(2):121].
        Nat Rev Nephrol. 2019; 15: 45-59
        • Go R.S.
        • Heien H.C.
        • Sangaralingham L.R.
        • Habermann E.B.
        • Shah N.D.
        Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA.
        Haematologica. 2018; 103: e123-e125
      3. Published recommendations. U.S. Preventive Services Task Force website.